Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rachel Parr

Vascular Surgery Greenville, SC Doctor of Osteopathy

NPI 1548649585 CMS profile 11300140

200 Patewood Dr Ste C300, Greenville, SC 29615

Open in the dashboard

General payments

$5,551

90 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Parr of Greenville, SC is reported in the CMS Open Payments database as having received $5,551 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,541 35
2024 General $1,754 35
2023 General $1,704 11
2022 General $157 2
2021 General $396 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Parr
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Rachel Parr were reported at $1,541. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Rachel Parr Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $396 $471 $158–$1,421 $132
2022 $157 $725 $222–$2,183 $149
2023 $1,704 $836 $257–$2,440 $160
2024 $1,754 $909 $252–$2,619 $164
2025 $1,541 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Endologix, Inc. $1,765 11 payments
  2. Medtronic, Inc. $703 10 payments
  3. W. L. Gore & Associates, Inc. $476 4 payments
  4. Shockwave Medical, Inc $473 12 payments
  5. Penumbra, Inc. $415 10 payments
  6. Surmodics, Inc. $369 14 payments
  7. Imperative Care, INc $210 3 payments
  8. Inari Medical, Inc. $183 4 payments
  9. Stryker Corporation $182 3 payments
  10. Integra LifeSciences Corporation $146 1 payment
  11. Other $630 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,198 85 payments
  2. Travel and Lodging $1,050 3 payments
  3. Education $304 2 payments
Products named General payments · program years 2021–2025
  1. ENDOCROSS Device $706 7 payments
  2. Torus Stent Graft System $706 7 payments
  3. ENDURANT IIS $441 4 payments
  4. Indigo System $347 7 payments
  5. GORE VIABAHN Endoprosthesis with Heparin $346 3 payments
  6. Pounce Venous Thrombectomy System $324 12 payments
  7. Alto Abdominal Stent Graft System $224 2 payments
  8. FLOWTRIEVER CATHETER, S $211 5 payments
  9. CT THROMBECTOMY SYSTEM KIT $211 5 payments
  10. SYMPHONY CATHETER $210 3 payments
  11. Other $2,535 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

83

Median for Vascular Surgery: 122

Drug cost

$8,628

Median for Vascular Surgery: $14,135

Branded share of claims

37.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 15 $7,886
Cilostazol Generic 26 $523
Clopidogrel Clopidogrel Bisulfate Brand 16 $118
Atorvastatin Calcium Generic 12 $61
Oxycodone Hcl Generic 14 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 128 billing codes

Paid by Medicare

$75,449

Medicare's payments for the services billed

Medicare patients

335

Average age 74

Services billed

850

163 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 57%
Ischemic heart disease 55%
Arthritis 48%
Diabetes 47%
Heart failure 46%
Atrial fibrillation 37%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record